The latest headlines across every section, pulled from official and open-access sources.
Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, dubbed “007,” next year.
Before a biotech deal gets signed, companies are already being tested by investors, pharma partners and their own pipelines. This episode looks at the pressure, timing and hard choices shaping what makes it to the table.
Biogen isn’t wasting any time integrating its multibillion-dollar purchase of Apellis, revealing plans to part ways with some of the biotech’s staffers and halt work on most of its research programs.
Epicrispr Biotechnologies has used its gene silencing tech to boost muscle mass in three patients with facioscapulohumeral muscular dystrophy, a clinical first for the debilitating disease with no approved treatments.
HeartBeam, the maker of a cable-free ECG system, moved CEO Robert Eno into a consulting role as part of a corporate restructuring aimed at expanding the company’s global market reach.